Literature DB >> 7838916

Influence of rate of administration of raclopride on akathisia and prolactin response.

G Movin-Osswald1, P Karlsson, M Hammarlund-Udenaes, L Farde.   

Abstract

The D2-dopamine receptor antagonist raclopride was administered to eight healthy male subjects, who had previously experienced akathisia following antipsychotic drugs. The influence of administration rate on onset, severity and duration of akathisia and on prolactin response was studied. Raclopride 3, 5 or 9 mg or placebo (P) was administered as single IV infusions during 10 min (R10 min/3 mg), 1 h (R1h/5 mg) or 4 h (R4h/9 mg) according to a randomized double-blind design. Despite a 24-fold difference in administration rate a similar peak raclopride concentration of about 350 nmol/l was obtained after all three infusions. Three of the eight subjects experienced akathisia following R10 min/3 mg and R1h/5 mg, respectively. After R4h/9 mg seven subjects experienced akathisia of longer duration but not more severe than after the short infusions. The incidence and duration of akathisia seem to be mainly related to the plasma raclopride concentrations over time, whereas the rate of administration might be more important for the severity. A maximal prolactin response was induced which was not markedly affected by the rate of administration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7838916     DOI: 10.1007/bf02244845

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  14 in total

1.  Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers.

Authors:  G Movin-Osswald; A L Nordström; M Hammarlund-Udenaes; A Wahlén; L Farde
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  Antipsychotic drug doses and neuroleptic/dopamine receptors.

Authors:  P Seeman; T Lee; M Chau-Wong; K Wong
Journal:  Nature       Date:  1976-06-24       Impact factor: 49.962

Review 3.  Neuroleptic-induced akathisia: a review.

Authors:  L A Adler; B Angrist; S Reiter; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  A rating scale for drug-induced akathisia.

Authors:  T R Barnes
Journal:  Br J Psychiatry       Date:  1989-05       Impact factor: 9.319

5.  Remoxipride: pharmacokinetics and effect on plasma prolactin.

Authors:  G Movin-Osswald; M Hammarlund-Udenaes
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

6.  Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers.

Authors:  C von Bahr; F A Wiesel; G Movin; P Eneroth; P Jansson; L Nilsson; S Ogenstad
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

7.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

Authors:  L Farde; H Hall; E Ehrin; G Sedvall
Journal:  Science       Date:  1986-01-17       Impact factor: 47.728

8.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

9.  Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride.

Authors:  L Farde
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.

Authors:  L Farde; F A Wiesel; P Jansson; G Uppfeldt; A Wahlen; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more
  1 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.